Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The source introductory threshold is rendered =60; the source table is preserved separately. This is not a newly verified label transcription.
Check source scope before reading a dose
GlobalRPh RX List - Maxipime
Product / population
Adult IV cefepime. Columns below correspond to the original usual regimen, not interchangeable infection choices.
Renal method
CrCl by Cockcroft-Gault using steady-state serum creatinine, mL/min.
Source revision
Revision date not established in selected retrieval.
Retrieved
2026-09-07
Local review status
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Daily post-HD timing is not the same as post-HD-only dosing
Label and institutional sources include daily dosing and post-dialysis-only schedules. Their indication, dialysis frequency, infusion, and exposure assumptions differ.
What to reconcile: Select one complete locally approved regimen; do not add a daily dose on top of a post-HD-only schedule.
Source difference identified; final patient-specific adjudication required.
GlobalRPh-hosted RX List · Adult IV cefepime. Columns below correspond to the original usual regimen, not interchangeable infection choices.
Renal method: CrCl by Cockcroft-Gault using steady-state serum creatinine, mL/min. Source date: Revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Maintenance schedules (all doses IV; intervals in hours):
CrCl
Usual 500 mg q12h
Usual 1 g q12h
Usual 2 g q12h
Usual 2 g q8h
30-60
500 mg q24h
1 g q24h
2 g q24h
2 g q12h
11-29
500 mg q24h
500 mg q24h
1 g q24h
2 g q24h
Below 11
250 mg q24h
250 mg q24h
500 mg q24h
1 g q24h
CAPD
500 mg q48h
1 g q48h
2 g q48h
2 g q48h
Hemodialysis: 1 g on day 1, then 500 mg every 24 hours, except febrile neutropenia requires 1 g every 24 hours. Give after dialysis on dialysis days. Infuse over approximately 30 minutes. The initial dose otherwise matches the normal-function regimen.
RDM33-rxlist-cefepime-C1 · Source locator: Adult renal dosage, Table 2 and footnotes; IV administration.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.